Carnot Labs, Inc. — SEC Form D Filing

Carnot Labs, Inc. filed an SEC Form D on July 23, 2026, reporting $4.95M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
July 23, 2026
Amount reported
$4.95M
Industry
Pharmaceuticals
Website
https://www.carnot.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

People suffer from various health conditions such as vaginal infections, allergic rhinitis, and other ailments, and couples need solutions for family planning.

Solution

Carnot Labs develops new pharmaceutical products to address these health issues and provides information and methods related to family planning and contraception.

Verdict

Investors backed this endeavor due to the perceived market size for common ailments and family planning, implying a bet on broad, undifferentiated demand rather than novel scientific breakthroughs. This cleared because of the established need for basic pharmaceutical products, not because of a compelling innovation or proprietary technology described. The lack of specificity regarding intellectual property or unique formulations inherently limited the upside to incremental market capture rather than disruptive gains.

Source: SEC EDGAR Form D filing